NRG1 and prostate cancer: Recent studies have supported the resistance to antiandrogens in the EGFR/ERK pathway through miR-146a-5p and the NRG1/HER3 axis in prostate cancer; however, obstructing NRG1/HER3 and inhibiting migration and growth strengthens ADCC in NRG1-positive pancreatic tumors and CAFs [138, 139].